Spots Global Cancer Trial Database for grade i neuroendocrine carcinoma
Every month we try and update this database with for grade i neuroendocrine carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | NCT03728361 | Grade I Neuroen... Grade II Neuroe... Grade III Neuro... Metastatic Neur... Neuroendocrine ... Recurrent Small... Refractory Smal... Lung Cancer Sta... Large Cell Neur... Neuroendocrine ... Small Cell Lung... Small-cell Lung... | Nivolumab Temozolomide | 18 Years - | Ohio State University Comprehensive Cancer Center |